$Polyrizon (PLRZ.US)$ 50

$Polyrizon (PLRZ.US)$
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Thursday, 30th January at 5:55 am
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Offi...

$Polyrizon (PLRZ.US)$
The divisional patent application for Polyrizon's Trap & Target platform represents a strategic move to strengthen their IP position in the rapidly growing intranasal drug delivery market, currently valued at over $50 billion globally. The technology's versatility in accommodating various drug types positions it as a potential game-changer for both existing and new therapeutic applications.
The platform's technical advantages are particula...

$Polyrizon (PLRZ.US)$
Game-Changing Nasal Drug Tech Could Transform Treatment of Seizures and Overdoses

$Polyrizon (PLRZ.US)$ possible retest in premarket tomorrow to 2.20 let go 🚀

$Polyrizon (PLRZ.US)$
With the global nasal spray market projected to reach over $23 billion by 2029, driven by increasing demand for innovative and effective solutions, Polyrizon is proud to take this step forward in advancing our PL-14 allergy blocker toward clinical trial," said Tomer Izraeli, CEO of Polyrizon. "By collaborating with Eurofins CDMO Amatsiaquitain...

$Polyrizon (PLRZ.US)$
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Thursday, 23rd January at 6:40 am
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts
Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasa...

$Polyrizon (PLRZ.US)$ 41.91% SI With Fintel showing 80K LTB at a CTB 177.42%

$Polyrizon (PLRZ.US)$ Reuters· 1 min ago
Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial